INT178097

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2004
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 9
Disease Relevance 5.97
Pain Relevance 0.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

aging (EDNRA) signal transducer activity (EDNRA) cell-cell signaling (EDN1)
cytoplasm (EDN1) cell proliferation (EDNRA) extracellular space (EDN1)
Anatomy Link Frequency
superior 1
EDN1 (Homo sapiens)
EDNRA (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 231 97.48 Very High Very High Very High
metalloproteinase 24 90.28 High High
cytokine 9 83.52 Quite High
Neurotransmitter 3 81.68 Quite High
Inflammation 15 68.76 Quite High
fibrosis 2 68.08 Quite High
Bioavailability 7 60.32 Quite High
Catecholamine 7 52.24 Quite High
Kinase C 9 46.12 Quite Low
Calcium channel 21 44.88 Quite Low
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 226 100.00 Very High Very High Very High
Cancer 195 99.64 Very High Very High Very High
Pulmonary Hypertension 293 93.12 High High
Metastasis 39 91.48 High High
Natriuresis 11 90.48 High High
Stress 18 87.36 High High
Apoptosis 54 86.68 High High
Hypoxia 32 86.64 High High
Ovarian Cancer 69 85.48 High High
Malignant Neoplastic Disease 18 79.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This suggests that low ET-1 doses have a greater affinity for ETB receptors to cause vasodilation, but increased levels of ET-1 leads to vasoconstriction by binding to ETA receptors.
ET-1 Binding (binding) of ETA associated with increased venous pressure under development
1) Confidence 0.21 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699797 Disease Relevance 0.77 Pain Relevance 0
In contrast, ETAR binds ET-1 with higher affinity than the other isoforms.
ET-1 Binding (binds) of ETAR
2) Confidence 0.19 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.26 Pain Relevance 0.08
This suggests that low ET-1 doses have a greater affinity for ETB receptors to cause vasodilation, but increased levels of ET-1 leads to vasoconstriction by binding to ETA receptors.
ET-1 Binding (binding) of ETA associated with increased venous pressure under development
3) Confidence 0.16 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699797 Disease Relevance 0.80 Pain Relevance 0
Engagement of the endothelin receptor by ET-1 induces tumor-promoting effects that are mediated by different downstream effectors, such as EGFR, VEGF COX-2, AKT, MAPK that could became the preferentially escaping pathways utilized by tumor cells.
ET-1 Binding (Engagement) of endothelin receptor associated with cancer
4) Confidence 0.15 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.97 Pain Relevance 0.14
Furthermore in these cells, ET-1 stimulated FAK and paxillin phosphorylation through ETAR binding [13] which directly correlated with tumor cell migration and invasion suggesting that ETAR antagonist can inhibit cell migration and possibly other FAK-associated processes which also contributes to invasion and metastasis in this tumor [28].
ET-1 Binding (binding) of ETAR associated with cancer, antagonist and metastasis
5) Confidence 0.14 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.83 Pain Relevance 0.20
ET-1 binds to 2 heptahelical G-protein-coupled receptors, named endothelin receptor-A (ETA) and endothelin receptor-B (ETB).
ET-1 Binding (binds) of ETA
6) Confidence 0.12 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.65 Pain Relevance 0.05
The ETA receptor binds ET-1 and ET-2 with greater affinity than it does ET-3, whereas the ETB receptor binds all three isoforms with equal affinity (Simonson and Dunn 1990).
ET Binding (binds) of ETA receptor
7) Confidence 0.09 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.59 Pain Relevance 0
The ETA receptor binds ET-1 and ET-2 with greater affinity than it does ET-3, whereas the ETB receptor binds all three isoforms with equal affinity (Simonson and Dunn 1990).
ET-1 Binding (binds) of ETA receptor
8) Confidence 0.09 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.58 Pain Relevance 0
Selective agents with relative ETA:ETB affinity of greater than 100:1 have been developed, eg, sitaxentan, relative affinity 6500:1, which have also been shown to reduce endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB affinity of 20:1 by in vitro assays and is therefore classed as a dual ERA.20 Although ETA selectivity is attractive, these selective agents have not been shown to be superior to bosentan in clinical trials.
endothelin-1 Binding (affinity) of ETA in superior associated with antagonist
9) Confidence 0.04 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.51 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox